8-K: Boston Scientific Exceeds Q3 Sales, EPS Guidance

Boston Scientific reported strong third-quarter 2025 financial results, surpassing its own guidance for net sales and adjusted earnings per share.

Summary

• Net sales reached $5.065 billion during the third quarter of 2025, representing a 20.3% increase on a reported basis, exceeding the company's guidance range of 17% to 19%.
• Organic net sales grew 15.3% compared to the prior year period, surpassing the company's guidance range of 12% to 14%.
• GAAP net income attributable to common stockholders was $755 million, or $0.51 per diluted share, exceeding the guidance range of $0.44 to $0.46 per share.
• Adjusted EPS was $0.75 for the period, surpassing the guidance range of $0.70 to $0.72 per share.
• The MedSurg segment achieved 16.4% reported net sales growth and 7.6% organic growth compared to the prior year period.
• The Cardiovascular segment achieved 22.4% reported net sales growth and 19.4% organic growth compared to the prior year period.
• United States (U.S.) net sales increased 27.0% on both a reported and operational basis.
• Europe, Middle East and Africa (EMEA) net sales increased 2.6% reported but declined (2.0)% operationally.
• Asia-Pacific (APAC) net sales increased 17.1% reported and 16.9% operational.
• Management decided to discontinue worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems, which had prior year global sales of approximately $50 million per quarter.

Sentiment

Score: 9

Explanation: The company significantly exceeded its own guidance for both net sales and adjusted EPS, demonstrating strong operational performance across most segments and regions. Strategic acquisitions and new product approvals further bolster future growth prospects, despite a minor operational decline in EMEA and the discontinuation of two aortic valve systems.

Positives

• Exceeded net sales guidance with $5.065 billion, a 20.3% reported increase (guidance 17-19%).
• Organic net sales growth of 15.3% surpassed guidance of 12-14%.
• GAAP diluted EPS of $0.51 exceeded guidance of $0.44-$0.46.
• Adjusted EPS of $0.75 surpassed guidance of $0.70-$0.72.
• Strong performance across businesses and regions, particularly in Cardiovascular (22.4% reported, 19.4% organic growth) and the U.S. market (27.0% reported/operational growth).
• Received Pharmaceuticals and Medical Device Agency (PMDA) approval in Japan for expanded labeling of the FARAPULSE Pulsed Field Ablation (PFA) System to include treatment of drug refractory, symptomatic persistent atrial fibrillation (AF).
• Commenced enrollment in the AGENT DCB STANCE trial to assess the safety and effectiveness of the AGENT Drug-Coated Balloon (DCB) in patients with previously untreated coronary lesions.
• Published in JAMA Neurology outcomes from the five-year INTREPID study demonstrating sustained benefits of deep brain stimulation in people with moderate to advanced Parkinson's disease, including improved motor function and quality of life.
• Completed asset acquisition with Elutia, Inc. to acquire the antibiotic-eluting EluPro BioEnvelope and the CanGaroo Envelope, designed to prevent certain post-operative complications for devices such as pacemakers and defibrillators.
• Announced agreement to acquire Nalu Medical, Inc., developer of the Nalu Neuromodulation System, which is designed to use peripheral nerve stimulation to deliver targeted relief for adults living with severe, intractable chronic pain of peripheral nerve origin.

Negatives

• Operational net sales in Europe, Middle East and Africa (EMEA) declined by 2.0% compared to the prior year period.
• Decision to discontinue worldwide sales of the ACURATE neo2 and ACURATE Prime Aortic Valve Systems, which had prior year global sales of approximately $50 million per quarter.

Risks

• Economic conditions, including the impact of foreign currency fluctuations.
• Future U.S. and global political, competitive, reimbursement, and regulatory conditions, including changing trade and tariff policies.
• Geopolitical events.
• Manufacturing, distribution, and supply chain disruptions and cost increases.
• Disruptions caused by cybersecurity events.
• Disruptions caused by public health emergencies or extreme weather or other climate change-related events.
• Labor shortages and increases in labor costs.
• Variations in outcomes of ongoing and future clinical trials and market studies.
• New product introductions.
• Expected procedural volumes.
• The closing and integration of acquisitions.
• Demographic trends.
• Intellectual property issues.
• Litigation.
• Financial market conditions.
• The execution and effect of business strategy, including cost-savings and growth initiatives.
• Future business decisions made by the company and its competitors.

Future Outlook

The company estimates full year 2025 reported net sales growth of approximately 20% and organic net sales growth of approximately 15.5%. Full year GAAP EPS is projected to be in the range of $1.97 to $2.01, with adjusted EPS estimated at $3.02 to $3.04. For the fourth quarter of 2025, reported net sales growth is expected to be between 14.5% and 16.5%, and organic growth between 11% and 13%, with GAAP EPS guidance of $0.48 to $0.52 and adjusted EPS of $0.77 to $0.79.

Management Comments

• "We delivered another exceptional quarter of strong performance across businesses and regions thanks to the winning spirit of our global team." Mike Mahoney, chairman and chief executive officer.
• "We are well-positioned for differentiated growth that is fueled by our category leadership strategy, relentless focus on innovation and commitment to scaling capabilities." Mike Mahoney.

Industry Context

Boston Scientific operates in the global medical technology sector, focusing on innovative solutions for cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases. The strong Q3 performance, particularly in Cardiovascular and U.S. markets, indicates robust demand for its medical devices and therapies. Strategic acquisitions and new product approvals, like the FARAPULSE PFA System, reinforce its position as a leader in key therapeutic areas, aligning with broader industry trends of innovation and market expansion in high-growth segments.

Comparison to Industry Standards

• The company highlights its 'category leadership strategy' and 'differentiated growth,' implying strong performance relative to the broader medical device industry.
• No specific comparisons to named competitors, industry benchmarks, or global project results are provided in the filing. However, exceeding its own guidance for organic growth and adjusted EPS suggests a strong competitive position and effective execution within its market segments.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, exceeding guidance, and a positive future outlook, which could lead to increased share value.
• Patients: Benefit from new and expanded product approvals (e.g., FARAPULSE PFA System, AGENT DCB trial, deep brain stimulation for Parkinson's) and strategic acquisitions aimed at improving patient care (e.g., Nalu Neuromodulation System).
• Employees: Management's recognition of the 'winning spirit of our global team' suggests positive morale, though restructuring related to discontinued products could impact some personnel.
• Customers (Physicians/Hospitals): Access to an expanding portfolio of innovative medical technologies and therapies.
• Creditors: Strong financial results and a positive outlook enhance the company's creditworthiness.

Next Steps

• Continue enrollment in the AGENT DCB STANCE trial to assess the safety and effectiveness of the AGENT Drug-Coated Balloon.
• Complete the acquisition of Nalu Medical, Inc., developer of the Nalu Neuromodulation System, subject to customary closing conditions.
• Host a conference call on October 22, 2025, at 8:00 a.m. ET to discuss the third quarter results.
• Focus on achieving the updated full year 2025 and fourth quarter 2025 financial guidance.

Key Dates

Recommendation

Boston Scientific delivered an exceptional third quarter, significantly outperforming its own guidance for both net sales and adjusted EPS. The company demonstrated robust organic growth across key segments like Cardiovascular and strong regional performance in the U.S. Strategic initiatives, including the approval of the FARAPULSE PFA System and the agreement to acquire Nalu Medical, position the company for continued innovation and market leadership. The positive full-year guidance further reinforces confidence in its sustained growth trajectory, making it an attractive investment.

Keywords

Boston Scientific, BSX, Medical Devices, Q3 2025 Earnings, Financial Results, Cardiovascular, MedSurg, Neuromodulation, FARAPULSE, AGENT DCB, Parkinson's Disease, Acquisition, Nalu Medical, Elutia, Aortic Valve Systems